|
EP3653212B1
(en)
|
2012-12-20 |
2023-04-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
CN113713091A
(zh)
|
2015-02-06 |
2021-11-30 |
新加坡国立大学 |
工程免疫细胞及其用途和生产方法
|
|
AU2016228080B2
(en)
|
2015-03-02 |
2020-11-12 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Reducing immune tolerance induced by PD-L1
|
|
MX2017014822A
(es)
|
2015-05-18 |
2018-04-30 |
Tcr2 Therapeutics Inc |
Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
|
|
CA2997551A1
(en)
*
|
2015-09-04 |
2017-03-09 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
JP7123794B2
(ja)
|
2015-12-09 |
2022-08-23 |
メモリアル スローン ケタリング キャンサー センター |
免疫細胞組成物及びそれを使用する方法
|
|
AU2017236069B2
(en)
*
|
2016-03-23 |
2021-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Fusion proteins of PD-1 and 4-1BB
|
|
EP3988111A1
(en)
|
2016-04-01 |
2022-04-27 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
US10654934B2
(en)
|
2016-04-01 |
2020-05-19 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CA3034691A1
(en)
|
2016-08-30 |
2018-03-08 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use for treating viral and other infections
|
|
WO2018064921A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Innovative Cellular Therapeutics CO., LTD. |
Use of chimeric antigen receptor modified cells to treat cancer
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
EP3544996A2
(en)
|
2016-11-22 |
2019-10-02 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
CN118581046A
(zh)
|
2016-11-22 |
2024-09-03 |
新加坡国立大学 |
用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
|
|
CN108148862B
(zh)
*
|
2016-12-05 |
2019-03-08 |
上海优卡迪生物医药科技有限公司 |
一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
|
|
US20190358263A1
(en)
|
2016-12-07 |
2019-11-28 |
Oslo Universitetssykehus Hf |
Compositions and Methods for Cell Therapy
|
|
US11649288B2
(en)
|
2017-02-07 |
2023-05-16 |
Seattle Children's Hospital |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
AU2018231190B2
(en)
*
|
2017-03-08 |
2023-05-25 |
Memorial Sloan Kettering Cancer Center |
Immune cell compositions and methods of use
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
US11648269B2
(en)
|
2017-08-10 |
2023-05-16 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
|
|
CN111433354A
(zh)
*
|
2017-09-26 |
2020-07-17 |
朗沃德大学 |
作为免疫疗法的pd1特异性嵌合抗原受体
|
|
CN109836493A
(zh)
*
|
2017-11-25 |
2019-06-04 |
深圳宾德生物技术有限公司 |
一种靶向cd19的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
US10561686B2
(en)
*
|
2018-01-12 |
2020-02-18 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
AU2019209428B2
(en)
|
2018-01-22 |
2025-06-26 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
TW202000229A
(zh)
|
2018-02-23 |
2020-01-01 |
美商安德賽特公司 |
Car t細胞療法之順序方法
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
SG11202010996QA
(en)
|
2018-05-23 |
2020-12-30 |
Nat Univ Singapore |
Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
WO2020086989A1
(en)
*
|
2018-10-25 |
2020-04-30 |
Innovative Cellular Therapeutics CO., LTD. |
Increase or maintaining t-cell subpopulations in adoptive t-cell therapy
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
WO2020116686A1
(ko)
|
2018-12-06 |
2020-06-11 |
고려대학교 산학협력단 |
인간 항-antxr 키메라 항원 수용체 및 이의 용도
|
|
CN109971842A
(zh)
*
|
2019-02-15 |
2019-07-05 |
成都美杰赛尔生物科技有限公司 |
一种检测CRISPR-Cas9脱靶效应的方法
|
|
WO2020172555A1
(en)
*
|
2019-02-21 |
2020-08-27 |
Regents Of The University Of Minnesota |
Genetically modified gamma delta t cells and methods of making and using
|
|
CA3129862A1
(en)
*
|
2019-03-01 |
2020-09-10 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a pd-1 ectodomain
|
|
JP2022531814A
(ja)
*
|
2019-03-12 |
2022-07-12 |
イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ |
改変細胞の増幅およびその応用
|
|
US11739136B2
(en)
*
|
2019-03-18 |
2023-08-29 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Inducible dominant negative PD-1 and uses in adoptive cell therapy
|
|
CN109868263A
(zh)
*
|
2019-03-29 |
2019-06-11 |
深圳精准医疗科技有限公司 |
重组单纯疱疹病毒及其制备方法和应用、重组载体的构建方法及其应用
|
|
AU2020276117A1
(en)
*
|
2019-05-16 |
2021-12-09 |
Memorial Sloan-Kettering Cancer Center |
Mesothelin cars and uses thereof
|
|
CN110423767A
(zh)
*
|
2019-07-12 |
2019-11-08 |
华东师范大学 |
表达可溶性pd-1的嵌合抗原受体car基因及应用
|
|
CN110592140A
(zh)
*
|
2019-09-30 |
2019-12-20 |
王清路 |
Pd-1基因缺陷型pd-1-cart细胞制剂的制法
|
|
US20210137983A1
(en)
*
|
2019-11-08 |
2021-05-13 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Nk cell expansion and uses thereof
|
|
EP4065695A4
(en)
|
2019-11-26 |
2023-08-09 |
ImmunityBio, Inc. |
Primary nk car constructs and methods
|
|
EP4100428A4
(en)
|
2020-02-04 |
2024-03-06 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
CHIMERIC ANTI-DINITROPHENOL ANTIGEN RECEPTORS
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
JP7198302B2
(ja)
*
|
2021-03-08 |
2022-12-28 |
一般財団法人 化学物質評価研究機構 |
Ｐｄ－１を介した免疫チェックポイント阻害剤の生物活性試験法
|
|
EP4215245A1
(en)
|
2022-01-19 |
2023-07-26 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment
|
|
WO2025184170A1
(en)
*
|
2024-02-27 |
2025-09-04 |
Overt Bio, Inc. |
Methods and compositions for improving t cell function in an immunosuppressive environment
|